|drug4087||standard of care Wiki||0.58|
|drug4039||questionnaire assesment Wiki||0.45|
There is one clinical trial.
Study to compare the efficacy and safety of colchicine and glucocorticoids compared with the standard of treatment for moderate/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a transicional care center
Description: Number of patients that a short cycle of steroids (with prednisone 60 mg/d, in a single dose, for 3 consecutive days) administered together with colchicine (at doses of 0.5 to 1.5 mg/d, adjusted for weight and renal function, for 3 days and maintenance of 0.5 mg/d for 14 days in total) reduces mortality from COVID-19 in this population by at least 20%, compared to the approved standard treatment at participating centers.Measure: Number of patients that a short cycle of steroids administered together with colchicine reduces mortality from COVID-19 Time: 28 days
Description: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment according to the incidence of: mild adverse event serious adverse events hypersensitivity (allergic) reactions of grade >=2Measure: Number and grade of adverse events at group of colchicine and glucocorticoids throughout the treatment and in the two weeks following treatment Time: 28 days
Description: Percentage of patients who stop medication due to adverse events.Measure: Percentage of patients who stop medication due to adverse events. Time: 28 days
Description: Severity of symptoms by COVID-19 in the two treatment arms (response to treatment to be assessed by overall survival at 28 days from the start of treatment).Measure: Severity of symptoms by COVID-19 in the two treatment arms Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports